GLP-1 Drugs: The Weight Loss Revolution Reshaping Markets
A Game-Changer in Healthcare
GLP-1 (glucagon-like peptide-1) receptor agonists, originally developed for diabetes treatment, have emerged as the most disruptive weight-loss drugs in history. With blockbuster names like Wegovy (Novo Nordisk) and Zepbound (Eli Lilly), these drugs have captured both medical and mainstream attention, fueling a stock market frenzy and reshaping multiple industries. The massive demand and clinical success of GLP-1 drugs have significantly expanded the dominance of Novo Nordisk and Eli Lilly in the pharmaceutical industry, but the ripple effects extend far beyond drugmakers.
